Health Care Professional Information
Pomegranate is a small fruit-bearing tree native to Asia but is cultivated in many parts of the world including the United States. The fruit juice extracted from the arils of the seeds is used in drinks and as a dietary supplement. Several studies have shown that pomegranate has antioxidant and antiatherosclerotic properties attributed to the presence of multiple polyphenols such as tannins, flavonols, anthocyanins and ellagic acid (1) (2). Pomegranate juice has been shown to suppress inflammatory cell signaling (1), inhibit prostate tumor growth and lower serum PSA levels (3) (4), and also inhibit aromatase activity, endogenous estrogen biosynthesis and breast cancer cell proliferation (5) in vitro.
Consumption of pomegranate juice was found to benefit patients with carotid artery stenosis (6), in those with hypertension (7), hyperlipidemia (21), mild to moderate erectile dysfunction (19), and in patients with coronary heart disease (CHD) (8), but had no effect in patients with chronic obstructive pulmonary disease (COPD) (9). Pomegranate juice appears to slow the rate of increase of PSA in men with high PSA levels (2). But this needs to be confirmed in large scale clinical trials.
Adverse effects associated with use of pomegranate juice are rare. There is, however, a concern that pomegranate juice can inhibit cytochrome P450 enzymes similar to grapefruit juice (10) (11). But other studies yielded mixed results (12).
Patients should be aware that pomegranate is not an approved cancer treatment.
- Cancer treatment and prevention
- Coronary heart Disease
- Ellagic acid
Mechanism of Action
Several studies have indicated that pomegranate juice has antioxidant and antiatherosclerotic properties due to the presence of multiple polyphenols such as tannins, flavonols, anthocyanins and ellagic acid. Punicalagin, an ellagitannin, is the most abundant polyphenol that accounts for >50% of the antioxidant activity (1) (2). Some commercial pomegranate juices are marketed with claims of higher antioxidant activity than green tea and red wine (13). However such effects could be due to colonic microflora metabolites and not the polyphenols present in the juice (14). Pomegranate extract can inhibit aromatase activity and decrease the endogenous synthesis of estrogen (5).
Studies in rats suggest that most punicalagin is absorbed but only 3-6% is excreted in the feces and urine suggesting that the majority is converted to CO2 or other undetectable metabolites (15). The metabolites that are present in urine in both rats and humans, 6H-dibenzo[b,d]pyran-6-one derivatives, are the products of intestinal microflora metabolizing the pomegranate tannins. A recent human study has shown that ellagic acid is absorbed from pomegranate juice and detected in plasma samples. It is unclear whether free ellagic acid is due to hydrolysis of the pomegranate ellagitannins, physiological pH, or gut microflora activity (16).
Pomegranate juice may increase the risk of rhabdomyolysis for patients on statin therapy possibly due to the inhibition of CYP 450 enzymes (17).
Diabetic patients should be careful because of the sugar content of pomegranate.
No significant adverse effects were seen with daily consumption of 8 ounces of pomegranate juice in men for over two years (2).
- Cytochrome P4503A substrates: Studies in rats indicate that pomegranate juice may inhibit cytochrome P450 3A (CYP3A) activity similar to grapefruit juice (10) (11). But a study in humans demonstrated that pomegranate juice did not alter clearance of intravenous or oral midazolam, whereas grapefruit juice is known to have this effect (12).
- CYP 2C9 substrates: A study done in rats showed that pomegranate juice inhibited CYP2C9 activity and increased tolbutamide bioavailability (18).
- Warfarin: According to a case report, pomegranate juice may interact with warfarin (20).
Literature Summary and Critique
Cerda B, Soto C, Albaladejo MD, et al. Pomegranate juice supplementation in chronic obstructive pulmonary disease: a 5-week randomized, double-blind, placebo-controlled trial. Eur J Clin Nutr 2006;60(2):245-253.Thirty men with COPD were given either pomegranate juice (providing 2.66 grams of polyphenols) or placebo for five weeks. No significant differences were found between the two groups for any of the study parameters including urinary 8-iso-PGF, respiratory function, hematological and serobiochemical markers, and clinical symptoms of COPD. The authors noted that none of the polyphenols present in pomegranate juice were detected in the plasma or urine of the patients. Instead, the major metabolites found were dibenzopyranone derivatives resulting from the pomegranate ellagitannins metabolized by colonic microflora. The authors suggest that understanding the different bioavailabilities of dietary polyphenols is essential before making claims of antioxidant-based health benefits.
Pantuck AJ, Leppert JT, Zomorodian N, et al. Phase II study of pomegranate juice for men with rising prostate-specific antigen following surgery or radiation for prostate cancer. Clin Cancer Res. 2006;12(13):4018-4026.
A phase II clinical trial was conducted with 46 men with rising PSA following surgery or radiotherapy. Subjects were given 240ml (8 ounces) of pomegranate juice daily until progression of disease. Researchers found a significant increase in the mean PSA doubling time following the study period. These results warrant further testing via a placebo-controlled study.
Sumner MD, Elliott-Eller M, Weidner G, et al. Effects of pomegranate juice consumption on myocardial perfusion in patients with coronary heart disease. Am J Cardiol 2005;96(6):810-814.
Forty-five patients with stable coronary heart disease (CHD) received 240mL/day of pomegranate juice or placebo for three months. After three months, stress-induced ischemia decreased in the pomegranate group (SDS -0.8 +/- 2.7), but an increase was observed in the placebo group. The authors conclude that pomegranate juice may be of benefit in improving stress-induced myocardial ischemia in CHD patients.
Dosage (Inside MSKCC Only)
This field is only visible to only Inside MSKCC users.
- Adams LS, Seeram NP, Aggarwal BB, Takada Y, Sand D, Heber D. Pomegranate juice, total pomegranate ellagitannins, and punicalagin suppress inflammatory cell signaling in colon cancer cells. J Agric Food Chem. Feb 8 2006;54(3):980-985.
- Pantuck AJ, Leppert JT, Zomorodian N, et al. Phase II study of pomegranate juice for men with rising prostate-specific antigen following surgery or radiation for prostate cancer. Clin Cancer Res. Jul 1 2006;12(13):4018-4026.
- Lansky EP, Jiang W, Mo H, et al. Possible synergistic prostate cancer suppression by anatomically discrete pomegranate fractions. Invest New Drugs. Jan 2005;23(1):11-20.
- Malik A, Afaq F, Sarfaraz S, Adhami VM, Syed DN, Mukhtar H. Pomegranate fruit juice for chemoprevention and chemotherapy of prostate cancer. Proc Natl Acad Sci U S A. Oct 11 2005;102(41):14813-14818.
- Kim ND, Mehta R, Yu W, et al. Chemopreventive and adjuvant therapeutic potential of pomegranate (Punica granatum) for human breast cancer. Breast Cancer Res Treat. Feb 2002;71(3):203-217.
- Aviram M, Rosenblat M, Gaitini D, et al. Pomegranate juice consumption for 3 years by patients with carotid artery stenosis reduces common carotid intima-media thickness, blood pressure and LDL oxidation. Clin Nutr. Jun 2004;23(3):423-433.
- Aviram M, Dornfeld L. Pomegranate juice consumption inhibits serum angiotensin converting enzyme activity and reduces systolic blood pressure.Atherosclerosis. Sep 2001;158(1):195-198.
- Sumner MD, Elliott-Eller M, Weidner G, et al. Effects of pomegranate juice consumption on myocardial perfusion in patients with coronary heart disease. Am J Cardiol. Sep 15 2005;96(6):810-814.
- Cerda B, Soto C, Albaladejo MD, et al. Pomegranate juice supplementation in chronic obstructive pulmonary disease: a 5-week randomized, double-blind, placebo-controlled trial. Eur J Clin Nutr. Feb 2006;60(2):245-253.
- Summers KM. Potential drug-food interactions with pomegranate juice. Ann Pharmacother. Jul-Aug 2006;40(7-8):1472-1473.
- Hidaka M, Okumura M, Fujita K, et al. Effects of pomegranate juice on human cytochrome p450 3A (CYP3A) and carbamazepine pharmacokinetics in rats.Drug Metab Dispos. May 2005;33(5):644-648.
- Farkas D, Oleson LE, Zhao Y, et al. Pomegranate juice does not impair clearance of oral or intravenous midazolam, a probe for cytochrome P450-3A activity: comparison with grapefruit juice.J Clin Pharmacol. Mar 2007;47(3):286-294.
- Gil MI, Tomas-Barberan FA, Hess-Pierce B, Holcroft DM, Kader AA. Antioxidant activity of pomegranate juice and its relationship with phenolic composition and processing. J Agric Food Chem. Oct 2000;48(10):4581-4589.
- Cerda B, Espin JC, Parra S, Martinez P, Tomas-Barberan FA. The potent in vitro antioxidant ellagitannins from pomegranate juice are metabolised into bioavailable but poor antioxidant hydroxy-6H-dibenzopyran-6-one derivatives by the colonic microflora of healthy humans. Eur J Nutr. Aug 2004;43(4):205-220.
- Cerda B, Llorach R, Ceron JJ, Espin JC, Tomas-Barberan FA. Evaluation of the bioavailability and metabolism in the rat of punicalagin, an antioxidant polyphenol from pomegranate juice. Eur J Nutr. Jan 2003;42(1):18-28.
- Seeram NP, Lee R, Heber D. Bioavailability of ellagic acid in human plasma after consumption of ellagitannins from pomegranate (Punica granatum L.) juice. Clin Chim Acta. Oct 2004;348(1-2):63-68.
- Sorokin AV, Duncan B, Panetta R, Thompson PD. Rhabdomyolysis associated with pomegranate juice consumption. Am J Cardiol. Sep 1 2006;98(5):705-706.
- Nagata M, Hidaka M, Sekiya H, et al. Effects of pomegranate juice on human cytochrome P450 2C9 and tolbutamide pharmacokinetics in rats. Drug Metab Dispos. Feb 2007;35(2):302-305.
- Forest CP, Padma-Nathan H, Liker HR. Efficacy and safety of pomegranate juice on improvement of erectile dysfunction in male patients with mild to moderate erectile dysfunction: a randomized, placebo-controlled, double-blind, crossover study. Int J Impot Res. 2007 Nov-Dec;19(6):564-7.
- Komperda KE. Potential interaction between pomegranate juice and warfarin. Pharmacotherapy. 2009 Aug;29(8):1002-6.
- Mirmiran P, Fazeli MR, Asghari G, Shafiee A, Azizi F. Effect of pomegranate seed oil on hyperlipidaemic subjects: a double-blind placebo-controlled clinical trial. Br J Nutr. 2010 Aug;104(3):402-6.
How It Works
BOTTOMLINE: Pomegranate was shown effective in lowering blood pressure and high cholesterol. More research is needed to know its benefits for cancer.
Pomegranate is a small fruit-bearing tree native to Asia. Juice from the seed pulp contains compounds known as polyphenols that may contribute to its activity. A few studies suggest pomegranate juice can benefit patients with heart disease and can lower cholesterol and blood pressure. It was shown in laboratory studies to prevent growth of cancer cells. In a human study, intake of pomegranate juice was found to have some benefit in patients with prostate cancer. But more clinical trials are needed to confirm such effects.
Patients should be aware that pomegranate is not an approved cancer treatment.
- Cancer prevention
Data from laboratory studies showed that pomegranate is effective against tumor cells. A single study in humans showed some indirect benefit of pomegranate juice for patients with prostate cancer. More studies are needed.
There is evidence from a few studies that pomegranate lowers cholesterol level.
A few small scale studies suggest that drinking pomegranate juice may reduce hypertension. More studies are needed to verify this effect.
Prostate CancerIn this study, 46 men with rising levels of Prostate Specific Antigen (PSA), a protein found in prostate cancer patients, were given 240ml (8 ounces) of pomegranate juice daily after surgery or radiation therapy. The rise of PSA was slowed after 54 months which suggests slower disease progression. More studies are needed to confirm such effects.
Forty-five patients with coronary heart disease (CHD) were assigned to receive 240mL/day of pomegranate juice or placebo for three months. Researchers reported a decrease in stress-induced ischemia (reduction in blood supply to heart muscle) following the study period. Pomegranate juice may benefit patients with CHD.
- Pomegranate juice may increase the risk of rhabdomyolysis (breakdown of muscle fibers and release of muscle fiber contents into circulation) for patients on statin therapy.
- Diabetic patients should be careful because of the sugar content of pomegranate.
Do Not Take If
- You are taking medications that interact with grapefruit juice (pomegranate may have effects similar to grapefruit juice.)
- You are taking warfarin (pomegranate juice may interact with warfarin).
No significant side effects were reported with use of pomegranate juice.
Last updated: April 18, 2011